Cynapsus Therapeutics Obtains Final Court Order and HSR Waiting Period Expires for Plan of Arrangement with Sunovion Pharmaceuticals
October 18, 2016 09:08 ET | Cynapsus Therapeutics Inc.
TORONTO, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing a fast-acting,...
Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals
October 13, 2016 16:00 ET | Cynapsus Therapeutics Inc.
TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing a fast-acting,...
ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement
September 28, 2016 19:27 ET | Cynapsus Therapeutics Inc.
TORONTO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH) is pleased to announce today that Institutional Shareholder Services (“ISS”), a leading...
Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease
August 29, 2016 06:00 ET | Cynapsus Therapeutics Inc.
TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration
August 15, 2016 06:00 ET | Cynapsus Therapeutics Inc.
TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...
Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease
August 12, 2016 06:00 ET | Cynapsus Therapeutics Inc.
- Results suggests APL-130277 rapidly and effectively converts patients from the OFF to full ON state - - Manuscript published online ahead of print -TORONTO, Aug. 12, 2016 (GLOBE NEWSWIRE) --...
Cynapsus Therapeutics Reports Second Quarter 2016 Financial Results and Recent Developments
August 10, 2016 16:10 ET | Cynapsus Therapeutics Inc.
- Recent Positive Dose Titration Data from Pivotal Phase 3 Clinical Program -- On Track for New Drug Application Submission in the First Half of 2017 - TORONTO, Aug. 10, 2016 (GLOBE NEWSWIRE) --...
Table1.jpg
Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
July 18, 2016 16:10 ET | Cynapsus Therapeutics Inc.
-- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO, July 18, 2016 (GLOBE NEWSWIRE)...
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
July 18, 2016 16:10 ET | Cynapsus Therapeutics Inc.
-- Company plans to initiate pivotal program in fourth quarter ---- Webcast with accompanying slides to discuss program tomorrow at 7:30 a.m. Eastern time --TORONTO, July 18, 2016 (GLOBE NEWSWIRE)...
Cynapsus Therapeutics Announces 2016 Analyst and Investor Day
July 06, 2016 06:00 ET | Cynapsus Therapeutics Inc.
TORONTO, July 06, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...